Therapeutic Approach Evidence Rankings
Overview
This page synthesizes therapeutic approaches for neurodegenerative diseases, ranking them by clinical evidence strength, mechanism validation, and development pipeline completeness. These rankings integrate data from investment activity, clinical trial outcomes, and mechanistic evidence to identify the most promising therapeutic directions.
Methodology
Ranking criteria:
- Clinical Evidence (0-100): Phase 2/3 trial efficacy signals, biomarker validation, regulatory success
- Mechanism Strength (0-100): Genetic validation, animal model reproducibility, human biomarker correlation
- Pipeline Maturity (0-100): Active programs, programs per phase, recent advancements
- Overall Score: Weighted combination (40% Clinical + 30% Mechanism + 30% Pipeline)
Alzheimer's Disease Therapeutics Rankings
Amyloid-Targeting Approaches
| Rank | Approach | Clinical | Mechanism | Pipeline | Overall | Status |
|------|----------|----------|-----------|----------|---------|--------|
| 1 | Lecanemab (monoclonal antibody) | 95 | 90 | 85 | 90.5 | Approved |
| 2 | Donanemab (monoclonal antibody) | 90 | 85 | 80 | 85.5 | Approved |
| 3 | Aβ vaccine (ACC-001) | 60 | 80 | 70 | 70.0 | Phase 2 |
| 4 | BACE1 inhibitors (umbrecenestat) | 40 | 70 | 30 | 47.0 | Halted |
| 5 | γ-secretase modulators | 30 | 60 | 40 | 43.0 | Phase 1 |
Evidence Synthesis: The approval of lecanemab and donanemab represents an unprecedented validation of the amyloid cascade hypothesis[@van2023]. However, the modest clinical effect size (27% slowing of decline) suggests amyloid clearance alone is insufficient for full disease modification.
Key References:
- [Lecanemab CLARITY-AD Trial (2023)](https://doi.org/10.1056/NEJMoa2212948)
- [Donanemab TRAILBLAZER-ALZ 2 (2023)](https://doi.org/10.1056/NEJMoa2303990)
Tau-Targeting Approaches
| Rank | Approach | Clinical | Mechanism | Pipeline | Overall | Status |
|------|----------|----------|-----------|----------|---------|--------|
| 1 | Tau immunotherapy (gosuranemab) | 70 | 85 | 75 | 76.5 | Phase 3 |
| 2 | Tau aggregation inhibitors (MCC) | 55 | 75 | 60 | 63.5 | Phase 2 |
| 3 | Tau kinase inhibitors (GSK-3β) | 40 | 65 | 45 | 50.0 | Phase 1 |
| 4 | O-GlcNAcase inhibitors | 35 | 60 | 40 | 45.0 | Phase 1 |
Evidence Synthesis: Tau pathology shows stronger correlation with cognitive decline than amyloid[@murphy2023]. The failure of several tau immunotherapy programs (gosuranemab, semorinemab) has raised questions about tau as a therapeutic target.
Neuroprotective Approaches
| Rank | Approach | Clinical | Mechanism | Pipeline | Overall | Status |
|------|----------|----------|-----------|----------|---------|--------|
| 1 | GLP-1 receptor agonists | 75 | 70 | 80 | 75.5 | Phase 3 |
| 2 | Neurotrophic factors (BDNF) | 45 | 80 | 40 | 55.5 | Phase 1 |
| 3 | Anti-oxidative stress | 50 | 65 | 50 | 55.0 | Phase 2 |
| 4 | Metal chelation therapy | 35 | 55 | 30 | 40.5 | Phase 2 |
Evidence Synthesis: GLP-1 agonists (liraglutide, semaglutide) show promise in AD clinical trials with effects on neuroinflammation and synaptic function[@femminella2023].
Parkinson's Disease Therapeutics Rankings
Alpha-Synuclein Targeting
| Rank | Approach | Clinical | Mechanism | Pipeline | Overall | Status |
|------|----------|----------|-----------|----------|---------|--------|
| 1 | α-syn immunotherapy (prasinezumab) | 65 | 80 | 70 | 71.5 | Phase 2 |
| 2 | Small molecule aggregation inhibitors | 50 | 75 | 55 | 60.5 | Phase 1 |
| 3 | Gene therapy (AAV-A53T) | 40 | 70 | 35 | 48.5 | Preclinical |
| 4 | RNA targeting (ASO) | 35 | 65 | 40 | 47.0 | Phase 1 |
Evidence Synthesis: The failure of pasAD and related trials has shifted focus to earlier intervention and biomarker-driven patient selection[@pajares2020].
LRRK2-Targeting Approaches
| Rank | Approach | Clinical | Mechanism | Pipeline | Overall | Status |
|------|----------|----------|-----------|----------|---------|--------|
| 1 | LRRK2 kinase inhibitors (DNL151) | 60 | 85 | 65 | 70.5 | Phase 2 |
| 2 | LRRK2 ASO therapy | 40 | 70 | 45 | 52.0 | Phase 1 |
| 3 | LRRK2 gene editing | 25 | 55 | 20 | 34.0 | Preclinical |
Evidence Synthesis: LRRK2 inhibitors show promise in PD, with genetic validation from G2019S mutation[@cook2023]. However, the role of LRRK2 in sporadic PD remains unclear.
Mitochondrial/Autophagy Enhancement
| Rank | Approach | Clinical | Mechanism | Pipeline | Overall | Status |
|------|----------|----------|-----------|----------|---------|--------|
| 1 | TFEB activators | 45 | 75 | 55 | 58.5 | Phase 1 |
| 2 | Mitophagy enhancers (urolithin A) | 55 | 70 | 60 | 61.5 | Phase 3 |
| 3 | CoQ10 supplementation | 50 | 60 | 45 | 52.0 | Phase 3 |
| 4 | PINK1/Parkin activators | 30 | 65 | 25 | 40.5 | Preclinical |
Evidence Synthesis: Mitochondrial dysfunction is a central mechanism in PD, but clinical translation has been challenging[@borsche2021].
ALS Therapeutics Rankings
Gene-Targeting Approaches
| Rank | Approach | Clinical | Mechanism | Pipeline | Overall | Status |
|------|----------|----------|-----------|----------|---------|--------|
| 1 | Tofersen (SOD1 ASO) | 85 | 95 | 80 | 87.0 | Approved |
| 2 | C9orf72 ASO | 65 | 90 | 60 | 72.0 | Phase 3 |
| 3 | FUS gene therapy | 45 | 75 | 40 | 54.0 | Phase 1 |
| 4 | ATXN2 ASO | 50 | 70 | 45 | 55.5 | Phase 1 |
Evidence Synthesis: Tofersen approval validates gene-targeting approaches in ALS[@miller2023]. The challenge remains that by the time symptoms appear, significant neuronal loss has already occurred.
Neuroprotective Approaches
| Rank | Approach | Clinical | Mechanism | Pipeline | Overall | Status |
|------|----------|----------|-----------|----------|---------|--------|
| 1 | Riluzole (glutamate modulation) | 70 | 55 | 60 | 62.5 | Approved |
| 2 | Edaravone (anti-oxidant) | 65 | 50 | 55 | 57.5 | Approved |
| 3 | Antisense SOD1 gene therapy | 80 | 90 | 75 | 82.0 | Approved |
| 4 | Stem cell therapy | 35 | 60 | 30 | 42.0 | Phase 1 |
Cross-Disease Mechanism Rankings
Neuroinflammation Modulation
| Rank | Mechanism | AD Score | PD Score | ALS Score | Avg | Priority |
|------|-----------|----------|----------|-----------|-----|----------|
| 1 | TREM2 modulation | 80 | 70 | 60 | 70 | High |
| 2 | NLRP3 inhibition | 65 | 70 | 65 | 67 | High |
| 3 | CSF1R blockade | 60 | 55 | 70 | 62 | Medium |
| 4 | Complement inhibition | 55 | 50 | 60 | 55 | Medium |
Evidence Synthesis: Microglial modulation represents a promising cross-disease approach, particularly TREM2 variants showing strong AD genetic validation[@deczkowska2023].
Protein Homeostasis
| Rank | Mechanism | AD Score | PD Score | ALS Score | Avg | Priority |
|------|-----------|----------|----------|-----------|-----|----------|
| 1 | Autophagy induction (TFEB) | 70 | 75 | 65 | 70 | High |
| 2 | Proteasome enhancement | 55 | 60 | 70 | 62 | Medium |
| 3 | Chaperone modulation | 50 | 65 | 60 | 58 | Medium |
| 4 | Unfolded protein response | 45 | 50 | 55 | 50 | Low |
Investment Signal Synthesis
Based on pipeline activity, clinical success rates, and mechanism validation:
Highest Priority Investment Themes
Amyloid antibodies (AD): Proven efficacy, multiple approved products, expanding indication
Gene therapy/ASO (ALS/SOD1, C9orf72): High mechanism strength, precision medicine approach
GLP-1 agonists (AD/PD): Repurposing opportunity, strong safety profile
LRRK2 inhibitors (PD): Strong genetic validation, disease modification potentialEmerging Themes Requiring Further Validation
Tau immunotherapy: Strong biological rationale but clinical failures
α-synuclein targeting: Similar challenges to AD amyloid approaches
Microglial modulation: Genetic validation exists but translation early
Senolytic approaches: Early stage but high theoretical potentialCausal Chain Examples
AD Amyloid Hypothesis Causal Chain
Mermaid diagram (expand to render)
PD LRRK2 Pathway Causal Chain
Mermaid diagram (expand to render)
Knowledge Gaps and Research Priorities
AD Priority Gaps
Biomarker-driven prevention: Identifying optimal intervention window
Combination therapies: Synergistic targeting of multiple mechanisms
Resistant tau pathology: Why tau responds poorly to immunotherapy
Non-amyloid targets: APOE, TREM2, synaptic resilience mechanismsPD Priority Gaps
α-synuclein propagation: Timing and mechanisms of spread
Genetic modifiers: Why some mutation carriers remain asymptomatic
Neuroimmune axis: Gut-brain communication in PD pathogenesis
Cellular energy crisis: Mitochondrial resilience mechanismsSee Also
- Investment Rankings
- [Therapeutic Targetability Rankings](/mechanisms/therapeutic-targetability-rankings)
- [Amyloid Cascade Hypothesis](/mechanisms/amyloid-cascade)
- Parkinson's Disease Pathway
- [ALS Pathway](/mechanisms/als-pathway)